title: The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients: A review of the British Columbia experience.
abstract: BACKGROUND
  The pp65 cytomegalovirus (CMV) antigenemia assay has been used as a means of guiding the pre-emptive therapy of CMV disease in solid organ transplant (SOT) recipients. Recently, concerns have been raised regarding the utility of the test to accurately and precisely detect viral activity early enough to reduce the morbidity and mortality associated with CMV OBJECTIVE: To determine the performance characteristics of the method of antigenemia testing of SOT recipients used at Vancouver General Hospital, Vancouver, British Columbia.
  
  
  METHODS
  All SOT recipients between January 1, 1999, and June 30, 2000, were retrospectively reviewed for six months following transplantation. Physical examination results, laboratory parameters, antigenemia results and treatment information were reviewed.
  
  
  RESULTS
  A total of 134 kidney, liver, lung and kidney-pancreas transplant recipients were included in the analysis. The overall performance characteristics of the antigenemia assay in predicting CMV disease included a sensitivity of 64%, a specificity of 81%, a positive predictive value of 76% and a negative predictive value of 71%. A mean of 18 days passed between the onset of signs and symptoms of CMV disease/syndrome and the first recorded positive antigenemia result, and only 26% of patients had a positive test result before the onset of symptoms. It was found that an antigenemia test breakpoint of at least one positive cell for defining a positive test provided the most sensitive and specific prediction, with increased odds of developing CMV disease.
  
  
  CONCLUSIONS
  Based on performance characteristics, the Vancouver General Hospital's current method of antigenemia testing to guide pre-emptive ganciclovir therapy in SOT patients is not optimal for the early detection of disease. Further study is needed on new molecular testing methods to determine if our ability to predict CMV disease can be improved.
authors.affiliation: Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital.
authors.forename: Erica D
authors.initials: ED
authors.lastname: Greanya
authors.forename: Nilufar
authors.initials: N
authors.lastname: Partovi
authors.forename: Eric M
authors.initials: EM
authors.lastname: Yoshida
authors.forename: R Jean
authors.initials: RJ
authors.lastname: Shapiro
authors.forename: Robert D
authors.initials: RD
authors.lastname: Levy
authors.forename: Chris H
authors.initials: CH
authors.lastname: Sherlock
authors.forename: Gwen M
authors.initials: GM
authors.lastname: Stephens